Recombinant shingles vaccine for frail and immunocompromised adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational longitudinal study follows adults eligible for the recombinant zoster vaccine to measure immune responses, clinical protection, and safety over time. It enrolls frail and immunocompromised subgroups including rheumatologic patients (including those on JAK inhibitors or CTLA4-Ig), people with solid tumors, hematologic malignancies or post-transplant/CAR-T recipients, and neurologic conditions such as multiple sclerosis. Immunogenicity assessments include VZV-specific T-cell and antibody measurements, while clinical endpoints include occurrence of herpes zoster and adverse events after vaccination. Participants are followed at scheduled clinic visits and blood draws at the coordinating center in Pavia, Italy.

Why it matters

Who can join: the full rules

3.1.1. Adult population (longitudinal study) General inclusion criteria Age ≥ 18 years Eligibility for RZV vaccination Written informed consent

Inclusion criteria for specific sub-groups:

Rheumatologic patients:

* rheumatoid arthritis diagnosis according to classification criteria of 1987 and/or 2018
* eligibility or in therapy with JAKis o CTLA4-Ig (monotherapy or DMARD combination)

Oncologic patients:

* confirmed histological diagnosis of solid tumour (any type)
* life expectancy ≥ 6 months
* Patients with cancer who have to start immunotherapy with or without chemotherapy/targeted therapy

Hematologic patients:

* Patients with haematological malignancy treated with drugs (chemotherapy, new drugs, target therapies) other than antibodies.
* Patients treated with anti-CD19 or CD20 or CD22 or CD30 or anti-PD1 antibodies with or without chemotherapy
* Patients receiving autologous or allogeneic transplantation or CAR-T cells

Neurologic patients:

* Multiple sclerosis (MS) diagnosis according to McDonald criteria 2017
* Eligibility or in therapy with first- or second-line immunosuppressive treatments

General Exclusion criteria No informed consent Previous HZ vaccination Documented reactions or allergies against vaccines Severe infections during the previous 3 months

3.1.2. Pediatric population (cross-sectional study) Inclusion criteria Written informed consent from parents legal tutor and child assent (depending on age) Serology for VZV positive

Hematologic patients:

* Patients with haematological malignancies treated with chemotherapy including experimental drugs and target therapies;
* Patients with haematological malignancies undergoing B-cell depleting treatments, e.g. CAR-T cell therapy or anti-CD20, antiCD22, anti-CD30, anti-CD19 monoclonal or bispecific antibodies
* Patients with haematological malignancies receiving allogeneic transplantation due to malignant or non-malignant diseases, including primary immunodeficiencies, hemoglobinopathies and acquired or inherited bone marrow failure syndrome.

Rheumatologic patients:

1. patients with connective tissue diseases (including systemic lupus erythematosus, SLE, juvenile dermathomyositis, JDM, and scleroderma) treated with B cell depleting therapies (anti-CD20);
2. patients with juvenile idiopathic arthritis (JIA) treated with TNF inhibitors. The corresponding disease control populations will be patients with the same diseases listed above, who are not receiving anti-CD20 or TNF inhibitors, respectively.

Where it's running

• Fondazione IRCCS Policlinico San Matteo, SC Microbiologia e Virologia
  Pavia, Pavia, Italy Recruiting

Study contacts

• Study coordinator: Fausto Baldanti, MD
• Email: f.baldanti@smatteo.pv.it
• Phone: +390382501039

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oral switch for bloodstream infections in immunocompromised children

  This trial tests whether switching from IV to oral antibiotics is just as safe as continuing IV therapy for children with bloodstream infections who are immunocompromised or have a central venous catheter.

  Recruiting at 4 sites Phase 4 Copenhagen University Hospital, Rigshospitalet · Aalborg and 3 other locations · NCT07923266

• Biomarkers of Inflammation, Infection, and Immunity in Critically Ill Patients

  This study tests whether blood biomarkers can predict illness severity and complications in adults admitted to intensive care with infection, including sepsis, and in immunocompromised or high-risk surgical patients.

  Recruiting University of Turin, Italy · Torino · NCT07682766

• Personalized immunological score to predict severe infections in transplant and immunocompromised patients

  This project will test whether a personalized immunological score can predict serious infections in transplant and other immunocompromised patients and help tailor their care.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07379554

• Nasal immune responses to respiratory viruses in immunocompromised and healthy adults

  See how nasal immune responses to respiratory viruses differ between immunocompromised adults and healthy adults.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT07295535

• Better testing for Pneumocystis in people with weakened immune systems

  This project will try a new qPCR test on non-invasive respiratory samples to see if it can detect Pneumocystis in immunocompromised adults compared with standard reference tests.

  Recruiting at 4 sites Assistance Publique - Hôpitaux de Paris · Paris and 3 other locations · NCT06890078

• Characterizing diversity and antifungal resistance in immunocompromised ICU patients with respiratory infections

  This study tests how diverse fungi and antifungal resistance appear in immunocompromised adults with pneumonia in the ICU.

  Recruiting New Valley University · Asyut · NCT06387667

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.